COCP Key Statistics, Chart & Performance
The current stock price of COCP is 1.11 USD. In the past month the price increased by 14.43%. In the past year, price decreased by -43.8%.
COCP Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to COCP. When comparing the yearly performance of all stocks, COCP is a bad performer in the overall market: 85.73% of all stocks are doing better.
COCP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to COCP. No worries on liquidiy or solvency for COCP as it has an excellent financial health rating, but there are worries on the profitability.
COCP Financial Highlights
Over the last trailing twelve months COCP reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS increased by 49.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.58% | ||
| ROE | -126.11% | ||
| Debt/Equity | 0 |
COCP Forecast & Estimates
8 analysts have analysed COCP and the average price target is 8.16 USD. This implies a price increase of 635.14% is expected in the next year compared to the current price of 1.11.
COCP Ownership
COCP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.22 | 981.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.07 | 526.82B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.12B | ||
| PFE | PFIZER INC | 8.02 | 145.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.42 | 112.50B | ||
| ZTS | ZOETIS INC | 19.66 | 54.93B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.83B | ||
| VTRS | VIATRIS INC | 5.52 | 14.81B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.55 | 12.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.94B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.31B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About COCP
Company Profile
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. The company is headquartered in Bothell, Washington and currently employs 11 full-time employees. The company went IPO on 2018-03-12. The firm is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). The company is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. The company has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. The company also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Company Info
COCRYSTAL PHARMA INC
19805 N Creek Pkwy
Bothell WASHINGTON 98011 US
CEO: Gary Wilcox
Employees: 11
Phone: 17864591831
COCRYSTAL PHARMA INC / COCP FAQ
Can you describe the business of COCRYSTAL PHARMA INC?
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. The company is headquartered in Bothell, Washington and currently employs 11 full-time employees. The company went IPO on 2018-03-12. The firm is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). The company is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. The company has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. The company also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
What is the current price of COCP stock?
The current stock price of COCP is 1.11 USD.
Does COCRYSTAL PHARMA INC pay dividends?
COCP does not pay a dividend.
What is the ChartMill rating of COCRYSTAL PHARMA INC stock?
COCP has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for COCRYSTAL PHARMA INC?
COCRYSTAL PHARMA INC (COCP) operates in the Health Care sector and the Pharmaceuticals industry.
Is COCRYSTAL PHARMA INC (COCP) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on COCP.
Can you provide the ownership details for COCP stock?
You can find the ownership structure of COCRYSTAL PHARMA INC (COCP) on the Ownership tab.